Maiocchi Sophie, Burnham Erica E, Cartaya Ana, Lisi Veronica, Buechler Nancy, Pollard Rachel, Babaki Danial, Bergmeier Wolfgang, Pinkerton Nathalie M, Bahnson Edward M
Department of Cell Biology and Physiology, University of North Carolina, Chapel Hill, NC, 27599, USA.
Curriculum in Toxicology and Environmental Medicine, University of North Carolina, Chapel Hill, NC, 27599, USA.
Adv Healthc Mater. 2025 Jun;14(15):e2404584. doi: 10.1002/adhm.202404584. Epub 2025 May 8.
Activated neutrophils release Neutrophil Extracellular Traps (NETs), comprising decondensed chromatin, peroxidases, and serine proteases, which aid in host defense but are also implicated in thrombosis and resistance to thrombolysis. Recombinant DNase 1, which degrades NETs, may aid in thrombus dissolution synergistically with fibrinolytics. However, its short half-life and susceptibility to plasma proteases limit its therapeutic applicability. To address these limitations, DNase1 is encapsulated into polymeric nanoparticles (DNPs) using inverse Flash Nanoprecipitation (iFNP), a scalable nanoparticle synthesis technique. Previously only used with model proteins, the study demonstrates for the first time the feasibility of extending iFNP to the encapsulation of therapeutic proteins. Conditions that promote DNase1 solubility, preserve activity, and demonstrate release resulting in ex vivo NET degradation are detailed. Furthermore, the use of neutrophils, the source of NETs, as carriers for DNPs to enhance targeted delivery is investigated. These findings confirm that DNP-loaded neutrophils maintain key functionalities, including viability and oxidative burst, and associate with in vitro blood clots to deliver nanoparticles, and DNase1 protein. This study not only extends the feasibility of applying iFNP to encapsulate therapeutic proteins into polymeric nanoparticles, a promising alternative to lipid nanoparticles, but also contributes to the emerging literature on neutrophils as delivery vectors for nanocarriers.
活化的中性粒细胞释放中性粒细胞胞外陷阱(NETs),其由解聚的染色质、过氧化物酶和丝氨酸蛋白酶组成,有助于宿主防御,但也与血栓形成和对溶栓的抵抗有关。重组DNase 1可降解NETs,它可能与纤溶药物协同作用,有助于血栓溶解。然而,其半衰期短且易受血浆蛋白酶影响,限制了其治疗应用。为解决这些局限性,利用反向闪蒸纳米沉淀法(iFNP,一种可扩展的纳米颗粒合成技术)将DNase1封装到聚合物纳米颗粒(DNPs)中。该研究首次证明了将iFNP扩展到治疗性蛋白质封装的可行性,此前iFNP仅用于模型蛋白。详细阐述了促进DNase1溶解、保持活性并证明其释放可导致体外NET降解的条件。此外,还研究了使用NETs的来源中性粒细胞作为DNPs的载体以增强靶向递送。这些发现证实,负载DNP的中性粒细胞保持关键功能,包括活力和氧化爆发,并与体外血凝块结合以递送纳米颗粒和DNase1蛋白。这项研究不仅扩展了应用iFNP将治疗性蛋白质封装到聚合物纳米颗粒中的可行性,这是脂质纳米颗粒的一种有前景的替代方案,而且还为中性粒细胞作为纳米载体递送载体的新兴文献做出了贡献。